Channelpedia

Kv8.2 Channel

142 automatically matched literature references

3

Gintant G et al. Evolution of strategies to improve preclinical cardiac safety testing.
Nat Rev Drug Discov, 2016 Feb 19 , ().

5

Arcangeli A et al. Novel perspectives in cancer therapy: Targeting ion channels.
Drug Resist. Updat., 2015 Jul-Aug , 21-22 (11-9).

6

Goodchild SJ et al. Sequence of gating charge movement and pore gating in HERG activation and deactivation pathways.
Biophys. J., 2015 Mar 24 , 108 (1435-47).

7

9

Männikkö R et al. Pharmacological and electrophysiological characterisation of hERG activator AZSMO-23.
Br. J. Pharmacol., 2015 Feb 12 , ().

10

Vijayvergiya V et al. Single channel and ensemble hERG conductance measured in droplet bilayers.
Biomed Microdevices, 2015 Feb , 17 (12).

13

20

23

Frolov RV et al. Celecoxib and ion channels: a story of unexpected discoveries.
Eur. J. Pharmacol., 2014 May 5 , 730 (61-71).

26

Hill AP et al. Kinetics of drug interaction with the Kv11.1 potassium channel.
Mol. Pharmacol., 2014 May , 85 (769-76).

27

Coleman N et al. New Positive KCa Channel Gating Modulators with Selectivity for KCa3.1.
Mol. Pharmacol., 2014 Jun 23 , ().

28

Radresa O et al. Roles of PKC Isoforms in PMA-Induced Modulation of the hERG Channel (Kv11.1).
J Biomol Screen, 2014 Jan 24 , ().

30

Gong Q et al. Identification of Kv11.1 isoform switch as a novel pathogenic mechanism of long-QT syndrome.
Circ Cardiovasc Genet, 2014 Aug , 7 (482-90).

32

Munoz C et al. Up-regulation of Kir2.1 (KCNJ2) by the serum & glucocorticoid inducible SGK3.
Cell. Physiol. Biochem., 2014 , 33 (491-500).

39

Rampe D et al. A history of the role of the hERG channel in cardiac risk assessment.
J Pharmacol Toxicol Methods, 2013 Jul-Aug , 68 (13-22).

41

43

Andreasen L et al. Genetic Modifier of the QTc Interval Associated With Early-Onset Atrial Fibrillation.
Can J Cardiol, 2013 Oct , 29 (1234-40).

46

Sharon D et al. Recognizing the KCNV2-related retinal phenotype. Author reply.
Ophthalmology, 2013 Nov , 120 (e80).

47

Khan AO Recognizing the KCNV2-related retinal phenotype.
Ophthalmology, 2013 Nov , 120 (e79-80).

52

54

Takanari H et al. Efficient and specific cardiac IK1 inhibition by a new pentamidine analogue.
Cardiovasc. Res., 2013 Jul 1 , 99 (203-14).

55

Vincent A et al. Pathognomonic (diagnostic) ERGs. A review and update.
Retina (Philadelphia, Pa.), 2013 Jan , 33 (5-12).

60

Crotti L et al. Long QT syndrome-associated mutations in intrauterine fetal death.
JAMA, 2013 Apr 10 , 309 (1473-82).

64

Abderemane-Ali F et al. Dual effect of phosphatidyl (4,5)-bisphosphate PIP2 on Shaker K+ channels.
J. Biol. Chem., 2012 Oct 19 , 287 (36158-67).

66

Hölter P et al. The retinal clock drives the expression of Kcnv2, a channel essential for visual function and cone survival.
Invest. Ophthalmol. Vis. Sci., 2012 Oct , 53 (6947-54).

68

Khan AO et al. 'Cone dystrophy with supranormal rod response' in children.
Br J Ophthalmol, 2012 Mar , 96 (422-6).

69

Vandenberg JI et al. hERG K(+) channels: structure, function, and clinical significance.
Physiol. Rev., 2012 Jul , 92 (1393-478).

71

Sergouniotis PI et al. High-resolution optical coherence tomography imaging in KCNV2 retinopathy.
Br J Ophthalmol, 2012 Feb , 96 (213-7).

73

Schweikart K et al. The effects of jaspamide on human cardiomyocyte function and cardiac ion channel activity.
Toxicol In Vitro, 2012 Dec 20 , 27 (745-751).

75

Thiadens AA et al. Clinical course, genetic etiology, and visual outcome in cone and cone-rod dystrophy.
Ophthalmology, 2012 Apr , 119 (819-26).

77

Cheng YM et al. Voltage-dependent gating of HERG potassium channels.
Front Pharmacol, 2012 , 3 (83).

78

Moreno C et al. Polyunsaturated Fatty acids modify the gating of kv channels.
Front Pharmacol, 2012 , 3 (163).

79

80

Zobor D et al. Rod and cone function in patients with KCNV2 retinopathy.
PLoS ONE, 2012 , 7 (e46762).

89

Bentzen BH et al. Pharmacological activation of Kv11.1 in transgenic long QT-1 rabbits.
J. Cardiovasc. Pharmacol., 2011 Feb , 57 (223-30).

93

Bett GC et al. Models of HERG gating.
Biophys. J., 2011 Aug 3 , 101 (631-42).

94

Jehle J et al. Novel roles for hERG K(+) channels in cell proliferation and apoptosis.
Cell Death Dis, 2011 , 2 (e193).

99

Larsen AP et al. Differential effects of Kv11.1 activators on Kv11.1a, Kv11.1b and Kv11.1a/Kv11.1b channels.
Br. J. Pharmacol., 2010 Oct , 161 (614-28).

100

Larsen AP Role of ERG1 isoforms in modulation of ERG1 channel trafficking and function.
Pflugers Arch., 2010 Oct , 460 (803-12).

103

Littink KW et al. Homozygosity mapping in patients with cone-rod dystrophy: novel mutations and clinical characterizations.
Invest. Ophthalmol. Vis. Sci., 2010 Nov , 51 (5943-51).

107

Zhou Q et al. Regulation of the voltage-insensitive step of HERG activation by extracellular pH.
Am. J. Physiol. Heart Circ. Physiol., 2010 Jun , 298 (H1710-8).

108

Andersen MK et al. Oligocone trichromacy: clinical and molecular genetic investigations.
Invest. Ophthalmol. Vis. Sci., 2010 Jan , 51 (89-95).

113

Larsen AP et al. Pharmacological activation of IKr impairs conduction in guinea pig hearts.
J. Cardiovasc. Electrophysiol., 2010 Aug 1 , 21 (923-9).

116

Bergren SK et al. Fine mapping of an epilepsy modifier gene on mouse Chromosome 19.
Mamm. Genome, 2009 Jun , 20 (359-66).

118

Einarsen K et al. Functional properties of human neuronal Kv11 channels.
Pflugers Arch., 2009 Aug , 458 (689-700).

119

Grunnet M et al. hERG1 channel activators: a new anti-arrhythmic principle.
Prog. Biophys. Mol. Biol., 2008 Oct-Nov , 98 (347-62).

120

Gentile S et al. The human ERG1 channel polymorphism, K897T, creates a phosphorylation site that inhibits channel activity.
Proc. Natl. Acad. Sci. U.S.A., 2008 Sep 23 , 105 (14704-8).

123

Bowlby MR et al. hERG (KCNH2 or Kv11.1) K+ channels: screening for cardiac arrhythmia risk.
Curr. Drug Metab., 2008 Nov , 9 (965-70).

124

126

Ben Salah S et al. Novel KCNV2 mutations in cone dystrophy with supernormal rod electroretinogram.
Am. J. Ophthalmol., 2008 Jun , 145 (1099-106).

127

Wissinger B et al. Cone dystrophy with supernormal rod response is strictly associated with mutations in KCNV2.
Invest. Ophthalmol. Vis. Sci., 2008 Feb , 49 (751-7).

129

Lundby A et al. KCNE3 mutation V17M identified in a patient with lone atrial fibrillation.
Cell. Physiol. Biochem., 2008 , 21 (47-54).

132

133

Bai X et al. Electrophysiological properties of human adipose tissue-derived stem cells.
Am. J. Physiol., Cell Physiol., 2007 Nov , 293 (C1539-50).

138

Ro S et al. Template switching within exons 3 and 4 of KV11.1 (HERG) gives rise to a 5' truncated cDNA.
Biochem. Biophys. Res. Commun., 2006 Jul 14 , 345 (1342-9).

139

141

Borlak J et al. Hallmarks of ion channel gene expression in end-stage heart failure.
FASEB J., 2003 Sep , 17 (1592-608).

142